Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06306482
Other study ID # SBA 23/390
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 7, 2024
Est. completion date March 7, 2026

Study information

Verified date March 2024
Source Hacettepe University
Contact Aynur Demirel, PhD
Phone +905545295057
Email aynur.demirel@hacettepe.edu.tr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to determine posture and posture related factors in patients with restrictive and obstructive lung disease.


Description:

It is aimed at investigating posture and posture related factors according to both type of disease and severity of disease in patients with restrictive and obstructive lung disease. The secondary purpose is to develop a model that determines correlations between posture and functional exercise capacity, respiratory and peripheral muscle strength, tightness of muscle, balance, and physical activity for each disease that will be included in this study. In accordance with these purposes, for each group, at least 15 patients with obstructive and restrictive lung disease will be included according to the inclusion and exclusion criteria for each disease, and 15 healthy controls will be included. Tests and questionnaires will be used in order to determine the severity of diseases. Lung function test and respiratory and peripheral muscle strength test will be performed. Time and Go test (TUG) and One minute sit to stand test will be performed. To evaluate the accessory respiratory muscles, a muscle tightness test will be performed for each muscle. Six Minute Walk Test (6 MWT) will be performed with an armband that measures energy expenditure for functional exercise capacity. To evaluate posture, the Corbin Postural Assessment Scale and photographic analysis will be used. Photographical analysis using software in lateral, posterior, and anterior views will be used for the cervical, thoracic, and lumbar regions. For angular and length measurements, anatomical landmarks will be determined and calculated in the regions. According to the results to be obtained, changes in posture according to the regions and posture related factors will be determined for each disease. It will guide professional working in this field.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date March 7, 2026
Est. primary completion date March 7, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Chronic Obstructive Pulmonary Disease Group Inclusion Criteria: - Over 55 years old, - Stage 1-2-3-4 according to the GOLD, - Being clinically stable for the last 4 weeks. Chronic Obstructive Pulmonary Disease Group Exclusion Criteria: - Receiving long-term oxygen therapy, - Having central and peripheral vestibular disease, - Communication problems, known mental and cognitive problems, - Having undergone any surgical intervention related to the spine within the last six months, Inclusion Criteria for the Cystic Fibrosis Group: - Being diagnosed with CF as a result of two sweat tests, - Being over 18 years old. Cystic Fibrosis Group Exclusion Criteria: - Being in acute pulmonary exacerbation period, - Receiving long-term oxygen therapy, - Having undergone any surgical intervention related to the spine within the last six months, Inclusion Criteria for the Asthma Group: - Diagnosed with asthma according to the Global Strategy for the Prevention and Treatment of Asthma (GINA), - Clinically stable for the last 1 month - Being over 18 years old. Asthma Group Exclusion Criteria: - Change in medication for the last 1 month. - Having undergone any surgical intervention related to the spine in the last six months, Inclusion Criteria for Bronchiectasis Group: - Being over 18 years old, - Being diagnosed with bronchiectasis other than cystic fibrosis, - Being clinically stable for the last 1 month. Bronchiectasis Group Exclusion Criteria: - Receiving long-term oxygen therapy, - Having undergone any surgical intervention related to the spine in the last six months. Diffuse Parenchymal Lung Diseases Inclusion Criteria: - Being diagnosed with diffuse parenchymal lung according to American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, - Being over 18 years old, - Having volunteered to participate in the research, - To be clinically stable and to have comorbid conditions (such as hypertension, diabetes) under control, Diffuse Parenchymal Lung Diseases Exclusion Criteria: - Having undergone any surgical intervention related to the spine within the last six months, - Having exacerbation in the last 3 months

Study Design


Locations

Country Name City State
Turkey Aynur Demirel Ankara
Turkey Hacettepe University Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of horizontal alignment of the head anterior view Angle between left and right tragus and horizontal will be measured via photographic analysis 1 day
Primary Evaluation of horizontal alignment of the trunk anterior view Angle between left and right acromion and horizontal will be measured via photographic analysis Angle between left and right anterior superior iliac spine and horizontal will be measured via photographic analysis.
Angle between left and right acromion and left and right anterior superior iliac spine will be measured via photographic analysis.
1 day
Primary Evaluation of horizontal alignment of the head lateral view Angle between left-right tragus and C7 spinous process and horizontal will be measured via photographic analysis. 1 day
Primary Evaluation of vertical alignment of the head lateral view Angle of acromion and tragus (left-right) and vertical will be measured via photographic analysis. 1 day
Primary Evaluation of horizontal alignment of the trunk lateral view Angle between anterior superior iliac spine and posterior superior iliac spina and horizontal will be measured via photographic analysis. 1 day
Primary Evaluation of vertical alignment of the trunk lateral view Angle between acromion and greater trochanter and vertical will be measured via photographic analysis. 1 day
Primary Evaluation of horizontal asymmetry trunk in posterior view Horizontal asymmetry of scapula in relation to T3 spinous process will be measured via photographic analysis. 1 day
Primary Evaluation of scapulae Investigation of posture by photographic analysis upward rotation/ anterior tilt/internal rotation of scapula, scapular elevation, and scapular abduction evaluations will be measured photographic analysis. 1 day
Primary Posture Posture will be examined via the Corbin Postural Assessment Scale. The total points of the Corbin Postural Assessment Scale range from 0 to 28 points. A higher point represents worse posture. 1 day
Secondary Functional exercise capacity Functional exercise capacity will be determined via Six Minute Walk Test. 1 day
Secondary Respiratory Muscle Strength Respiratory muscle strength will be assessed using a mouth pressure device according to American Thoracic Society/ European Respiratory Society guidelines. 1 day
Secondary Lung function Lung function will be assessed via a spirometer according to American Thoracic Society/ European Respiratory Society guidelines. 1 day
Secondary Dyspnea Dyspnea will be assessed via The Modified Medical Research Council. The Modified Medical Research Council consists of five grades. A higher grades represents severe dyspnea level. 1 day
Secondary Peripheral muscle strength Peripheral muscle strength will be assessed via hand dynamometer. 1 day
Secondary Lower extremity capacity One minute sit to stand test will be used for lower extremity capacity. 1 day
Secondary Energy expenditure An armband will be used to assess energy expenditure during six minute walk test. 1 day
Secondary Balance and Fall risk Time up and go test will be used to assess balance and fall risk 1 day
Secondary Tightness of muscle Pectoralis minör, pectoralis majör, adductor and internal rotator muscles, sternocleidomastoideus, and trapezius muscle tightness tests will be performed during musculoskeletal examination using a tape. 1 day
Secondary Severity of disease for patients with COPD Global Initiative for Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Pulmonary A,B,E assessment Tool will be used for patients with COPD. According to the Global Initiative for Chronic Obstructive Pulmonary Disease, the severity of airflow limitation (Forced Expiratory Volume in 1 s) was determined as mild (= 80%), moderate (50-80%), severe (30-50%), and very severe (<30%). According to Global Initiative for Chronic Obstructive Pulmonary ABE assessment Tool, patients classified group A, B, and E using symptom status and airflow limitation. 1 day
Secondary Severity of disease for patients with bronchiectasis Patients with non- cystic fibrosis bronchiectasis will be classified into three groups according to the Forced Expiratory Volume in 1 s, Age, Chronic colonisation, Extension, Dyspnea level. According to this classification system, patients will be classified as 0-2 points mild, 3-4 moderate, 5-7 severe bronchiectasis. 1 day
Secondary Diffusion capacity for patients with diffuse parenchymal lung diseases Carbon Monoxide Diffusion Capacity test with single breath method will be used for patients with diffuse parenchymal lung diseases. 1 day
Secondary Symptoms for patients with COPD Chronic Obstructive Pulmonary Disease Assessment Test will be used to determined symptoms in patients with COPD. The total score of Chronic Obstructive Pulmonary Disease Assessment Test changes from 0 to 40 points, and 10 points is the accepted cut-off point for COPD. 1 day
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Terminated NCT03309358 - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis Phase 1
Completed NCT03682354 - ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Completed NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Completed NCT00269256 - Stress, Environment, and Genetics in Urban Children With Asthma N/A
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Active, not recruiting NCT00115297 - Montelukast for Early Life Wheezing Phase 2/Phase 3
Completed NCT00091767 - Genetic Studies in Difficult to Treat Asthma: TENOR N/A
Completed NCT00094276 - Intervention for Improving Asthma Care for Minority Children in Head Start N/A
Completed NCT00233168 - Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents N/A
Completed NCT00089752 - Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3